Statement of Translational Relevance
Interleukin (IL)-6 is involved in the pathogenesis of B-cell lymphoid malignancies and multiple myeloma. Overproduction of IL-6 from affected lymph nodes is responsible for systemic manifestations in Castleman's disease (CD), an atypical lymphoproliferative disorder.
In this phase I, open-label, dose-finding study, we demonstrate that siltuximab, a chimeric anti-IL-6 monoclonal antibody, has clinical activity as a single agent in patients with B-cell nonHodgkin's lymphoma or multiple myeloma (MM). A high rate of clinical response was seen in CD patients, including similar rates of radiologic response in all 3 histological types of multicentric CD. There was no apparent dose-related or cumulative toxicity across all 3 disease indications after a maximum duration of treatment of 60.5 months. A dose of 12 mg/kg every 3 weeks was recommended based on the high response rates in CD and the sustained C-reactive protein suppression. Randomized studies of siltuximab are ongoing in multicentric CD and MM. 
INTRODUCTION
Interleukin (IL)-6 is involved in the pathogenesis of B-cell lymphoid malignancies and plays an important role in multiple myeloma (MM), inducing proliferation and preventing programmed cell death in neoplastic plasma cells (1) (2) (3) (4) . High serum IL-6 levels correlate with worse prognosis and survival in lymphoma and MM patients (5-11). Castleman's disease (CD) is an atypical lymphoproliferative disorder. Overproduction of IL-6 from affected lymph nodes is responsible for systemic manifestations (12) . Targeting IL-6 signaling by tocilizumab, a humanized IL-6 receptor antibody, improved or resolved systemic symptoms and associated laboratory abnormalities with reduction in lymphadenopathy in plasma-cell multicentric CD (MCD) patients in a Japanese phase II study (13, 14) .
Siltuximab is a chimeric (murine-human) monoclonal antibody (mAb) with high binding affinity for human . This study evaluated the safety and pharmacokinetics of siltuximab in patients with B-cell non-Hodgkin's lymphoma (NHL), MM, or CD. Based on emerging data (18), dosage regimens with escalating dose intensity were planned to evaluate dose-response relationship, safety, and to select the dose for future studies. Interim results from the study have been reported on 23 CD patients (19). Herein, we report integrated doseescalation, safety, pharmacokinetics, pharmacodynamics, and efficacy results from a completed phase I study of siltuximab in 67 treated patients with NHL (n=17), MM (n=13), or CD (n=37, including plasma-cell, hyaline vascular, and mixed cellularity histology) and including mature safety data on prolonged treatment for up to 60.5 months.
METHODS

Patients
Research. lymphoma, follicular lymphoma, mantle cell lymphoma); MM; or symptomatic CD (multicentric/unresectable unicentric). Other key entry criteria and corticosteroid use rules have been previously described (19). This study was conducted according to the Declaration of Helsinki and was approved by the local institutional review board for each study site. All patients provided written informed consent.
Efficacy
Disease assessments were performed on days 36 and 57 and every 9 to 12 weeks thereafter for cohorts 1 to 6 and every 2 cycles from cycle 4 to 18 and then every 4 cycles for cohort 7. For NHL patients, disease response was based on investigator assessment of Cheson criteria (1999) (20) except for CLL/SLL, which were evaluated by Cheson criteria (1996) (21), and WM, which was evaluated by Weber criteria (2003) (22). For MM patients, disease response was based on investigator assessment of Bladé criteria (1998) (23). For CD patients, disease response was evaluated using Cheson criteria (1999) modified to include the assessment of measurable cutaneous lesions as previously described (19) and was independently reviewed by central radiology facility CoreLab (Princeton, NJ).
Clinical benefit response (CBR) was evaluated by an investigator for CD patients on days 36 and 57 and during extended treatment for cohorts 1 to 6 and every cycle for cohort 7. CBR was defined as improvement from baseline in ≥1 and no worsening in the remaining of the following: ≥2 g/dL increase in hemoglobin without transfusions; ≥1 grade decrease in fatigue; ≥1 grade decrease in anorexia; ≥2°C decrease in fever/return to 37°C or improvement in night sweats; ≥5% increase in weight; or ≥25% decrease bidimensionally in the size of the largest lymph node (19). Best CBR during the study is reported.
Pharmacodynamics
Levels of C-reactive protein (CRP), a downstream marker for IL-6 activity, significantly correlated with IL-6 levels in NHL patients (24), and anti-IL-6 treatment decreased CRP in Blymphoproliferative disorders and MM (15) . We therefore measured CRP concentrations as a surrogate marker for IL-6 bioactivity.
Research. IL-6 is a potent inducer of hepcidin, a liver-produced iron regulatory hormone implicated in anemia of lymphoma, MM, and CD (25-27). Siltuximab treatment has been associated with hemoglobin increases and hepcidin decreases in renal cancer patients in an earlier clinical study (28) . Hepcidin evaluation was performed retrospectively in MM and CD patients to further investigate the association between changes in hepcidin levels and hemoglobin improvement.
Methods for the biomarker analyses are described elsewhere (Supplementary Methods).
Statistical Analyses
Descriptive statistics were used to summarize data. No formal hypothesis testing was planned. A minimum of 6 patients was planned per cohort for Cohorts 1 to 5. Six (with potential expansion to 12) patients were planned for Cohort 6. Twelve and up to 20 patients were planned, respectively, for Cohorts 7a and 7b. Other statistical methods have been previously described (19).
Research. 
RESULTS
From June 2005 to September 2009, 67 patients were enrolled at 9 centers in the US.
Forty-seven (70%) patients discontinued study treatment, including 13 (19%) due to disease progression, 7 (10%) due to AEs (including 4 possibly related to study agent), and none due to death (Fig. 1) Of the 67 treated patients, 17 (25%) had NHL, 13 (19%) had MM, and 37 (55%) had CD (Table 1) . Approximately half of patients were male in NHL (53%), MM (46%), and CD (51%) disease types; and most were Caucasian (94%, 77%, 73%, respectively). Median age was 69, 57, and 48 years in NHL, MM, and CD, respectively. Fifty-four (81%) patients had prior therapy, 10 (15%) had autologous transplant, 8 (12%) had radiotherapy, and 7 (10%) had cancer-related surgery. The median number of prior systemic therapies was 2 (range 0, 17). Median disease duration in NHL, MM, and CD patients was 3.5 (range 0.4, 16.6) years, 3.0 (range 1.4, 9.5) years, and 0.7 (0.1, 7.8) years, respectively. A majority of patients had a Karnofsky performance status score of 80 (NHL 29%, MM 62%, CD 41%) or ≥90 (NHL 59%, MM 31%, CD 41%).
Twelve (32%) of 37 CD patients were newly diagnosed at baseline, 35 had multicentric disease, and only 1 was HHV-8-positive.
Safety
Research. Patients received a median of 16 (maximum 110) siltuximab doses ( Table 2 ). Median treatment duration was 8.5 (maximum 60.5) months, including a clinical hold due to drug supply issue that interrupted the treatment of 7 patients for 2.5 to 5.3 months. No DLTs were observed in cohorts 1 to 6 per DMC review after each cohort. After completion of the cohort 6 safety review, the DMC determined that the safety profiles of siltuximab administered as a 1-hour versus 2-hour IV infusion were similar; therefore, the 1-hour infusion was used for all future patients, and enrolled patients were allowed to switch to 1-hour infusion.
No dose-related toxicity was apparent. AEs reported in ≥15% of patients overall regardless of relationship to siltuximab are shown in Fig. 2A ; most AEs were low grade except for grade 3−4 neutropenia (21%) and grade 3 hypertension (9%). Hypertension was manageable by antihypertensive medications and did not lead to any study-agent discontinuations. Forty-four (66%) patients had all-grade AEs of infection; the all-grade infection event rate per patient-year in NHL, MM, and CD patients was 5.2, 1.8, and 1.9, respectively, and was 2.1 in all treated patients. Most infections were low grade and not reported in more than 1 patient. The most common infections regardless of relationship to siltuximab were upper respiratory tract infection (URTI; 39%), urinary tract infection (UTI; 16%), sinusitis (12%), cellulitis (9%), nasopharyngitis (7%), and ear infection (6%); among these, 1 case of URTI and 4 cases of cellulitis occurred at grade ≥3.
The most frequently reported all-grade AEs considered possibly related to siltuximab were thrombocytopenia (25%), neutropenia (19%), hypertriglyceridemia (19%), leukopenia (18%), hypercholesterolemia (15%), and anemia (10%; Fig. 2B ). However, none of these events led to dose delay or discontinuation except for neutropenia and thrombocytopenia (each n=1). Three deaths occurred within 90 days of the last siltuximab dose, including 2 (3%) because of an AE (PD in a NHL patient considered not related to siltuximab and renal impairment in a MM patient considered unlikely related to siltuximab) and 1 CD patient who died due to other reasons (sepsis after receiving subsequent chemotherapy that was considered not related to siltuximab).
There was no evidence of cumulative toxicity upon prolonged exposure. Twenty-nine patients were treated for 1 year or longer; none of these patients discontinued treatment due to an AE, and there were no treatment-related deaths. There was no increase in the incidence of grade ≥3 AEs or SAEs over time. Grade ≥3 AEs regardless of relationship to siltuximab were reported more frequently in year 0−1 (52%) and year 1−2 (41%) than in year 2−3 (21%) and year >3 (33%). SAEs regardless of relationship to siltuximab did not increase over time (n=4 in year 0−1, n=5 in year 1−2, n=2 in year 2−3, n=4 in year >3).
Pharmacokinetics
Research. For cohorts 1 to 6, a summary of siltuximab pharmacokinetic parameter estimates after the first administration and day 43 administration are presented in Table 3 . Serum concentrations of siltuximab declined in a bi-exponential manner, with a mean terminal-phase half-life following the first dose ranging from 17.73 to 20.64 days and the mean clearance ranging from 4.03 to 4.59 mL/day/kg. Following the first dose and repeated doses, approximate doseproportional increases in maximum observed concentration (Cmax) and area under the serum concentration-time curve (AUC 0-t ) were observed. The accumulation following repeated doses was consistent with the terminal-phase half-life following the first dose, suggesting no timedependent changes in pharmacokinetics. No apparent differences in pharmacokinetic profiles were observed when comparing patients with NHL, MM, or CD ( Supplementary Fig. S1 ).
Immunogenicity
None of the 31 patients with appropriate samples, defined as having ≥1 sample collected after dosing, were positive for antibodies to siltuximab.
Efficacy
Of the 14 evaluable NHL patients, 2 (WM treated with 6 mg/kg q2w, extranodal marginal zone B-cell MALT lymphoma treated with 12 mg/kg q3w) had confirmed PRs lasting 4.1 and 6.2 months, 7 had SD (range 0.9, 5.6 months), and 5 had PD. Of the 13 evaluable MM patients, 2 (treated with 6 mg/kg qw and 12 mg/kg q3w) had confirmed CR with response duration lasting 11.7 and 16.7 months, 8 had SD (range 0.5, 18.0 months), and 3 had PD. Supplementary Fig. S2 shows serum CRP and gamma M-spike levels over time for 1 of the 2 MM patients with CR. in all cohorts at almost all timepoints tested. This trend was most apparent in cohort 7, possibly due to longer siltuximab treatment in these CD patients (Fig. 3 ).
Of the 37 CD patients evaluable for CBR, 32 (87%) improved in ≥1 component, 28 (76%) improved in ≥2 components, 21 (57%) improved in ≥3 components, and 16 (43%) improved in ≥4 components ( Table 4 ). The majority of CD patients improved in fatigue (78%), size of the largest lymph node (65%), weight (60%), and fever/night sweats (51%) with siltuximab.
Median overall survival was 67.8 months for all treated patients, 33.1 months for NHL patients (with a median duration of 2.5 years follow up), and was not reached for patients with MM or CD. Only 6 of the 13 MM patients had died after a median of 3.3 years of follow-up.
Only 3 (8%) of the 37 CD patients had died after a median follow-up of 2.4 years.
Pharmacodynamics
Decreases from baseline in CRP concentration were observed as early as day 8 in cohorts 1 to 6 across all disease types, with median levels remaining low at later timepoints. CD patients treated with 12 mg/kg q3w showed greater CRP decrease (Cohort 7b: 77% median reduction)
than those treated with 9 mg/kg q3w (Cohort 7a: 52% median reduction, both at cycle 3 day 1) (Supplementary Table S1 ).
Twenty-seven (42%) of 64 tested patients showed evaluable baseline IL-6 concentrations above the level of detection. Circulating serum IL-6 levels were not predictive of clinical response in the limited number of patients tested.
Hepcidin decreased post-treatment in most (97%) MM and CD patients, with 75% of these patients showing an increase in hemoglobin of ≥1.5 g/dL.
There were no apparent treatment-related changes in the serum levels of a select panel of 
DISCUSSION
In this large phase I study of 67 treated patients with B-cell NHL, MM, or CD, the multiple dosing regimens of the anti-IL-6 mAb siltuximab tested in all 3 disease types were well tolerated with no DLTs observed. The most frequently reported AEs considered by investigators to be possibly related to siltuximab were thrombocytopenia, neutropenia, hypertriglyceridemia, leukopenia, hypercholesterolemia, and anemia. These events were all laboratory-related, transient, and reversible. Interestingly, hemoglobin increase was also observed in some patients, especially in MCD (Fig. 3) . Sixty-six percent of patients had at least 1 infection during treatment, although most were low-grade. The infection event rate per patient-year was 5.2, 1.8, and 1.9 for NHL, MM, and CD patients, respectively, which is not unexpected in each disease type, especially through an observation period encompassing multiple years. A contribution of IL-6 inhibition to the occurrence or severity infections cannot be excluded a priori but is impossible to quantify in this dataset since a background incidence is to be expected. In a recently published randomized placebo-controlled study of the anti-IL-6 receptor mAb tocilizumab in systemic juvenile idiopathic arthritis (29) , the event rate of infections per patient-year reported in the placebo group (2.9) and in the tocilizumab group (3.4 during double-blind phase, 3 .0 during open-label treatment) was similar to the event rate of 2.1 per patient-year in our study.
Reversible infusion reactions in this study were reported in only 4 (6%) patients, who were all able to continue siltuximab with or without prophylactic treatment without recurrence. Only 4 (6%) patients discontinued due to a possibly siltuximab-related AE, and no siltuximab-related deaths were reported through >3 years of treatment. The safety profile of siltuximab was similar at all dose levels. Siltuximab could be given for a prolonged duration without evidence of For the same dose and schedule, the first-dose pharmacokinetic parameters estimates of Cmax and AUC 0-t are similar to the values previously reported in renal cell carcinoma patients (18).
Additionally, the observed accumulation following repeated doses to steady-state in this study is consistent with the previously reported half-life of approximately17 days.
Siltuximab-neutralized antibody-IL-6 complexes distort current immunologic-based IL-6 quantification methods, therefore, accurate quantification of IL-6 in post-treatment samples is not currently possible. Additionally, systemic IL-6 levels do not necessarily reflect IL-6 concentrations in the tumor niche or the IL-6 dependence of tumor cells, which are more likely to influence response to treatment (31). Therefore we measured CRP as a pharmacodynamic marker for IL-6 bioactivity. CD patients treated with 12 mg/kg q3w showed greater decreases in CRP than those treated with 9 mg/kg q3w. This is in agreement with the observed dose-response relationship for clinical benefit in CD patients. However, for MM and NHL, the small number of patients in each dose cohort makes it difficult to examine the true relationship between CRP suppression and clinical response. Importantly, in addition to the high response rates in seen in CD patients, the radiologic response rate was similar in all 3 histologic types of CD (6/17 plasma-cell, 5/18 hyaline vascular, and 1/2 mixed cellularity). To date, response has only been reported with tocilizumab in plasmacell CD patients (14) . Because the majority of CD patients with unicentric disease have the hyaline vascular variant (32, 33), it is therefore possible that siltuximab may also have clinical benefit in unicentric CD patients who are unsuitable for surgery.
The clinical activity of siltuximab was most evident at the higher dose levels. The efficacy data suggest a dose response, with 1 CR and 8 of 11 PRs seen in CD patients treated at 12 mg/kg, regardless of dosing schedule. Among the 4 responders in NHL or MM patients, durable response was seen with 12 mg/kg q3w, which supports the above observation in CD responders. Furthermore, 12 mg/kg q3w siltuximab was safe and well tolerated, with no DLTs observed. To date, no therapy has been shown to be effective for MCD in a randomized trial. The response rates observed in this MCD population with severe disease, as evidenced by their low performance scores, is likely to be an important addition to the available therapeutic options for MCD should these preliminary efficacy estimates be borne out in an ongoing randomized controlled trial (35). In addition, preliminary pharmacokinetic/pharmacodynamic modeling results showed that this dose would decrease CRP to below 1 mg/L in MCD patients (36).
Pharmacokinetic/pharmacodynamic modeling suggests that lower doses, including 9 mg/kg q3w, 
Figure 3
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